2-Aminoindane (2-AI) is an aminoindane and research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug.

[2][3] Synthetic aminoindanes were originally developed in the context of anti-Parkinsonian drugs as a metabolite of rasagiline and as a tool to be used in psychotherapy.

Deaths related to their toxic effects have been observed both in the laboratory in animal studies and in clinical encounters.

[4] 2-AI is a rigid analogue of amphetamine and partially substitutes for it in rat drug discrimination tests.

[19] Sweden's public health agency suggested classifying 2-AI as a hazardous substance, on June 24, 2019.